Sam Brusco, Associate Editor08.01.23
Terumo’s MicroVention subsidiary announced publication of the WEB-IT five-year follow-up data and addition of two sizes to its WEB aneurysm embolization system.
According to the company, WEB is the most well studied intrasaccular device available in the marketplace today, with 7 good clinical practice (GCP) studies and over 200 peer-reviewed publications. The two new sizes (SL 6x2 and SL 7x2) allow treating different sizes and shapes of aneurysms.
WEB treats brain aneurysms inside the aneurysm sac to disrupt blood flow while sealing the neck and protecting the dome with the company’s MicroBraid tech. Further, WEB’s five-year follow-up results showed long-term safety and effectiveness.
WEB, according to the company, overcomes the challenges of multiple devices to treat wide-neck bifurcation aneurysms. The single device solution can reduce procedure times and provide less exposure to radiation. It offers a robust scaffold for endothelialization and has flexibility with the ability to resheath, reposition, and retrieve the device.
“From the GCP studies, there is currently a total of 1464 patient-years and counting, from 601 patients, during which no patient has experienced bleeding or re-bleeding from a WEB-treated aneurysm—a remarkable track record of effectiveness over a large, accumulated experience,” Dr. David J. Fiorella, Director of the Stony Brook Cerebrovascular Center, Co-Director of the Stony Brook Cerebrovascular and Comprehensive Stroke Center, and Professor of Neurosurgery and Radiology, told the press.
“It is great to have long term follow up on this large, adjudicated GCP study. At this time, there is no device that has been shown to be safer for aneurysm patients than WEB. So, if a patient with a wide-neck bifurcation aneurysm can be treated with WEB, that ought to be the primary consideration,” added Dr. Adam Arthur, James T Robertson Professor and Chair at The University of Tennessee Health Science Center.
“MicroVention’s WEB Aneurysm Embolization System is now the most studied intrasaccular device available today, underscoring our commitment to physicians and patients alike to provide innovative, advanced medical device technology proven by long-term clinical safety and efficacy data,” said Carsten Schroeder, president and CEO, MicroVention, Inc. “We will continue to work side-by-side with leading physicians around the world to identify the evolving needs in patient care, and then transform those insights into innovative technologies that help to save patient lives.”
According to the company, WEB is the most well studied intrasaccular device available in the marketplace today, with 7 good clinical practice (GCP) studies and over 200 peer-reviewed publications. The two new sizes (SL 6x2 and SL 7x2) allow treating different sizes and shapes of aneurysms.
WEB treats brain aneurysms inside the aneurysm sac to disrupt blood flow while sealing the neck and protecting the dome with the company’s MicroBraid tech. Further, WEB’s five-year follow-up results showed long-term safety and effectiveness.
WEB, according to the company, overcomes the challenges of multiple devices to treat wide-neck bifurcation aneurysms. The single device solution can reduce procedure times and provide less exposure to radiation. It offers a robust scaffold for endothelialization and has flexibility with the ability to resheath, reposition, and retrieve the device.
“From the GCP studies, there is currently a total of 1464 patient-years and counting, from 601 patients, during which no patient has experienced bleeding or re-bleeding from a WEB-treated aneurysm—a remarkable track record of effectiveness over a large, accumulated experience,” Dr. David J. Fiorella, Director of the Stony Brook Cerebrovascular Center, Co-Director of the Stony Brook Cerebrovascular and Comprehensive Stroke Center, and Professor of Neurosurgery and Radiology, told the press.
“It is great to have long term follow up on this large, adjudicated GCP study. At this time, there is no device that has been shown to be safer for aneurysm patients than WEB. So, if a patient with a wide-neck bifurcation aneurysm can be treated with WEB, that ought to be the primary consideration,” added Dr. Adam Arthur, James T Robertson Professor and Chair at The University of Tennessee Health Science Center.
“MicroVention’s WEB Aneurysm Embolization System is now the most studied intrasaccular device available today, underscoring our commitment to physicians and patients alike to provide innovative, advanced medical device technology proven by long-term clinical safety and efficacy data,” said Carsten Schroeder, president and CEO, MicroVention, Inc. “We will continue to work side-by-side with leading physicians around the world to identify the evolving needs in patient care, and then transform those insights into innovative technologies that help to save patient lives.”